RxDoctor Payments DataLook up a doctor →

Alexander Nimri, MD

Nephrology · Phoenix, AZNPI 1467666123

Payments from drug & device makers

$132,559in general payments, 2019–2025

Across 455 payments — averaging $291.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$64K
  • Vertex$51K
  • Amgen$3K
  • Travere Therapeutics, Inc.$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • Mallinckrodt Hospital Products Inc.$2K
  • plus $10K from 35 others

What the payments were for

  • Food & beverage$20,69898%
  • Education$5152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$132,559 in reported general payments places this provider in the 90th percentile of 259 nephrology providers in Arizona.

See all nephrology providers in Arizona

Medicare billing

Part B allowed, 2024
$174,253
Medicare patients
259
Services billed
1,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol160$150,618
VelphoroSucroferric Oxyhydroxide17$60,612
KerendiaFinerenone50$55,485
OzempicSemaglutide34$46,318
JardianceEmpagliflozin32$28,934
VeltassaPatiromer Calcium Sorbitex13$18,961
Sevelamer Carbonate47$9,873
LokelmaSodium Zirconium Cyclosilicate18$9,005
DapagliflozinDapagliflozin Propanediol15$7,482
Nifedipine ErNifedipine25$613
Fluconazole19$563
Bumetanide11$425
Losartan Potassium54$288
Metoprolol Succinate29$267
Tamsulosin Hcl16$182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$63,783$159,623178 claims
Fresenius USA Marketing, Inc.Velphoro$695$60,61217 claims
BayerKerendia$1,461$55,48550 claims
Novo NordiskOzempic$631$46,31834 claims
Boehringer IngelheimJardiance$165$28,93432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 259 nephrology providers in Arizona.

Other nephrology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →